76.02MMarket Cap-6.74P/E (TTM)
1.580High1.460Low13.85KVolume1.510Open1.470Pre Close21.17KTurnover0.03%Turnover RatioLossP/E (Static)49.05MShares2.55052wk High1.45P/B65.23MFloat Cap1.12052wk Low--Dividend TTM42.08MShs Float16.120Historical High--Div YieldTTM8.16%Amplitude1.120Historical Low1.529Avg Price1Lot Size
MediciNova Stock Forum
13 mins ago
Medicinova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of Mn-166 (Ibudilast) in ALS (Combat-ALS Clinical Trial) at the 35TH International Symposium on ALS/Mnd
MediciNova Inc - Positive Correlations Observed Between 6-Month and 12-Month Data
📊⚡️📊
MediciNova Inc - Patent Is Expected to Expire No Earlier Than May 26, 2042
MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver
MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis
MediciNova (NASDAQ: MNOV) announced it will receive monetary damages following the settlement of Sanofi-Novartis litigation. The company plans to use this non-dilutive fundingto support ongoing clinical development programs, particularly focusing on their late-stage pipeline targeting inflammatory, metabolic, and neurodegenerative diseases. The settlement validates MediciNova's in...
No comment yet